To obtain a new compound, a non-peptidic compound, having excellent somatostatin receptor agonistic action, and useful as a preventive/therapeutic agent for e.g. diabetes.
This compound is shown by formula I [A-ring and B-ring are each a (substituted) aromatic hydrocarbon or (substituted) aromatic heterocycle; Z is a (substituted) cyclic group or (substituted) chain hydrocarbon; R1 is H, a (substituted) hydrocarbon or the like; R2 is a (substituted) amino; D and G are each a lone pair or (substituted) bivalent hydrocarbon; E is a lone pair, CON(Ra) or the like; I is a bivalent group; X is two Hs, O or N; formula II represents a single or double bond; Y is N when formula II represents a double bond, being O or the like when formula II represents a single bond], pref. 3,5- trans-N-(2-fluorobenzyl)-5-(3-aminomethylphenyl)-1-(4-biphenylmethyl)-7-chloro-2- oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide or the like. It is recommended that the compound of formula I is obtained, for example, by condensation reaction between a compound of formula III and a compound of formula IV.
SUZUKI NOBUHIRO
MIKI TAKASHI
